The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2021 | Using clinical trials to drive treatment approaches in lung cancer
Andrew Robinson, MD, MSc, FRCPC, Queen’s University, Kingston, ON, discusses the importance of using clinical trials to drive treatment approaches and summarizes the role of immunotherapies in the treatment of squamous non-small cell lung cancer (NSCLC), highlighting data on pembrolizumab and chemotherapy from the KEYNOTE-407 trial (NCT02775435). This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
